Exagen reaffirms $70M-$73M 2026 revenue guidance as it targets $600-$650 ASP over time (NASDAQ:XGN)
ExagenExagen(US:XGN) Seeking Alpha·2026-05-12 13:31

技术访问问题 - 用户需在浏览器中启用Javascript和cookies以确保未来正常访问 [1] - 启用广告拦截器可能导致访问被阻止 用户需禁用广告拦截器并刷新页面 [1]

Exagen reaffirms $70M-$73M 2026 revenue guidance as it targets $600-$650 ASP over time (NASDAQ:XGN) - Reportify